Voretigene Neparvovec (Luxturna): First FDA-Approved In Vivo Gene Therapy for an Inherited Disease

Before Luxturna, patients with biallelic RPE65 mutation-associated retinal dystrophy had no treatment to slow their progressive visual loss. The condition, caused by a deficient or absent RPE65 enzyme critical for the visual cycle, typically produces severe night blindness in childhood and leads to legal or complete blindness by adulthood. Retinal gene therapy research had been underway for years, with early-phase trials at the University of Pennsylvania showing that a functional RPE65 gene could be delivered to retinal pigment epithelium cells and produce meaningful visual improvements, evidence that supported moving to a registration trial.

Jean Bennett and Albert Maguire at the University of Pennsylvania led the scientific and surgical development that eventually produced the registration trial. Maguire performed the precise subretinal injections required to deposit the adeno-associated virus vector directly beneath the photoreceptor layer, a technically demanding procedure that distinguishes in vivo gene therapy delivery from any prior treatment. Katherine High, who co-founded Spark Therapeutics to commercialize the work, oversaw the transition from academic research to a regulatory submission. The phase 3 registration trial enrolled 31 patients at two clinical sites, Children's Hospital of Philadelphia and the University of Iowa, a number that reflects the rarity of RPE65 mutations rather than any shortcut in design.

On December 19, 2017, the FDA approved voretigene neparvovec, making it the first gene therapy delivered directly into the human body to clear the agency. The primary endpoint was a bilateral multi-luminance mobility test, a novel instrument the investigators developed specifically for this trial because no validated measure existed for the condition. Treated patients navigated a standardized obstacle course at light levels ranging from one lux to four hundred lux significantly better than controls, and full-field light sensitivity also improved. The approval required a post-marketing registry to collect long-term durability data, an acknowledgment that the follow-up from a 31-patient trial could not answer all questions.

The procedural template Luxturna established, subretinal or targeted tissue delivery, AAV vector serotype selection, single-dose design, and a companion registry requirement, became a reference point for later in vivo gene therapy programs. Regulators and developers alike studied the Luxturna submission when building dossiers for hemophilia B gene therapies and other ocular indications. The approval also forced a conversation about pricing for single-administration curative therapies; Spark listed voretigene at $425,000 per eye, prompting outcomes-based rebate agreements with payers. Longer-term follow-up of the earlier phase 1 cohorts has generally shown the benefit holding up over multiple years.